Helio Health and Fulgent Genetics announced a late-breaking poster presentation on HelioLiver’s performance at The Liver Meeting® 2021, hosted by AASLD — presented by David J. Taggart, PhD.
IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ — Helio Health (“Helio”), an AI-driven healthcare company developing blood-based early cancer detection tests, and Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based genetic testing company, today announced its upcoming late-breaking poster presentation on the performance of HelioLiver, a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers for the detection of hepatocellular carcinoma (HCC), at The Liver Meeting® 2021. The annual meeting is hosted by the American Association for the Study of Liver Diseases (AASLD) and will be held virtually November 12–15, 2021.
Details of the poster presentation are as follows:
- Poster Title: A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma
- Publication Number: LP44
- Session Title: Late-breaking Abstract Posters
- Presenter: David J. Taggart, PhD, NRCC(CC) — Laboratory Director and Vice President of Laboratory Operations and Regulatory Affairs, Helio Health Inc.
The poster presentation will be available for viewing by the attendees of The Liver Meeting® throughout the entire meeting.
About Helio Health
Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.
About Fulgent Genetics
Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times.
About the Helio Health and Fulgent Genetics Partnership
In a strategic partnership announced in August of 2021, Helio Health and Fulgent Genetics plan to commercialize and co-brand HelioLiver, a cell-free DNA (cfDNA) methylation blood test that incorporates protein markers and demographics for the detection of hepatocellular carcinoma (HCC). Fulgent is responsible for laboratory operations, supply chain operations, and marketing and sales, initially focused in the U.S. and Canada. Helio provides intellectual property and continued support across research and development, publication development, market access and sales, as well as reimbursement operations.
SOURCE Helio Health and Fulgent Genetics, Inc. View source version on PR Newswire.